

ALEXION PHARMACEUTICALS INC  
 Form 4  
 February 05, 2014

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL  
 OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 SQUINTO STEPHEN P

(Last) (First) (Middle)

C/O ALEXION  
 PHARMACEUTICALS INC, 352  
 KNOTTER DRIVE

(Street)

CHESHIRE, CT 06410

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
 ALEXION PHARMACEUTICALS  
 INC [ALXN]

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 02/03/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)  
 \_\_\_ Director \_\_\_ 10% Owner  
X Officer (give title below) \_\_\_ Other (specify below)  
 EVP, Chief Global Ops. Officer

6. Individual or Joint/Group Filing(Check Applicable Line)  
X Form filed by One Reporting Person  
 \_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				(A) or (D)	Price		
				Code	V	Amount	
Common Stock, par value \$0.0001 per share	02/03/2014		S	852 <sup>(1)</sup>	D	\$ 157.14	102,216 D
Common Stock, par value \$0.0001 per share	02/04/2014		S	3,200 <sup>(1)</sup>	D	\$ 153.63	99,016 D

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

Common Stock, par value \$\$.0001 per share	02/04/2014	S	3,300	D	\$ 157.1	95,716	D
Common Stock, par value \$\$.0001 per share	02/04/2014	M	7,876	A	\$ 22.9	103,592	D
Common Stock, par value \$\$.0001 per share	02/04/2014	M	6,250	A	\$ 42.66	109,842	D
Common Stock, par value \$\$.0001 per share	02/04/2014	M	10,813	A	\$ 78.88	120,655	D
Common Stock, par value \$\$.0001 per share	02/04/2014	M	3,800	A	\$ 93.83	124,455	D
Common Stock, par value \$\$.0001 per share	02/04/2014	S	29,637	D	\$ 155	94,818	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
--	--	--------------------------------------	--	--------------------------------	---	--	---

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	\$ 22.9	02/04/2014	M			7,876	04/28/2010	01/28/2030	Common Stock, par value \$.0001 per share	7,876
Option to Purchase Common Stock	\$ 42.66	02/04/2014	M			6,250	05/02/2011	02/02/2021	Common Stock, par value \$.0001 per share	6,250
Option to Purchase Common Stock	\$ 78.88	02/04/2014	M			10,813	05/03/2012	02/03/2022	Common Stock, par value \$.0001 per share	10,813
Option to Purchase Common Stock	\$ 93.83	02/04/2014	M			3,800	05/06/2013	02/06/2023	Common Stock, par value \$.0001 per share	3,800

## Reporting Owners

### Reporting Owner Name / Address

### Relationships

Director    10% Owner    Officer    Other

SQUINTO STEPHEN P  
C/O ALEXION PHARMACEUTICALS INC  
352 KNOTTER DRIVE  
CHESHIRE, CT 06410

EVP, Chief Global Ops. Officer

## Signatures

/s/ Michael Greco  
Attorney-in-Fact

02/05/2014

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.